Literature DB >> 11823861

Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.

Laurent Monney1, Catherine A Sabatos, Jason L Gaglia, Akemi Ryu, Hanspeter Waldner, Tatyana Chernova, Stephen Manning, Edward A Greenfield, Anthony J Coyle, Raymond A Sobel, Gordon J Freeman, Vijay K Kuchroo.   

Abstract

Activation of naive CD4(+) T-helper cells results in the development of at least two distinct effector populations, Th1 and Th2 cells. Th1 cells produce cytokines (interferon (IFN)-gamma, interleukin (IL)-2, tumour-necrosis factor (TNF)-alpha and lymphotoxin) that are commonly associated with cell-mediated immune responses against intracellular pathogens, delayed-type hypersensitivity reactions, and induction of organ-specific autoimmune diseases. Th2 cells produce cytokines (IL-4, IL-10 and IL-13) that are crucial for control of extracellular helminthic infections and promote atopic and allergic diseases. Although much is known about the functions of these two subsets of T-helper cells, there are few known surface molecules that distinguish between them. We report here the identification and characterization of a transmembrane protein, Tim-3, which contains an immunoglobulin and a mucin-like domain and is expressed on differentiated Th1 cells. In vivo administration of antibody to Tim-3 enhances the clinical and pathological severity of experimental autoimmune encephalomyelitis (EAE), a Th1-dependent autoimmune disease, and increases the number and activation level of macrophages. Tim-3 may have an important role in the induction of autoimmune diseases by regulating macrophage activation and/or function.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11823861     DOI: 10.1038/415536a

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  537 in total

1.  CEACAM1 regulates TIM-3-mediated tolerance and exhaustion.

Authors:  Yu-Hwa Huang; Chen Zhu; Yasuyuki Kondo; Ana C Anderson; Amit Gandhi; Andrew Russell; Stephanie K Dougan; Britt-Sabina Petersen; Espen Melum; Thomas Pertel; Kiera L Clayton; Monika Raab; Qiang Chen; Nicole Beauchemin; Paul J Yazaki; Michal Pyzik; Mario A Ostrowski; Jonathan N Glickman; Christopher E Rudd; Hidde L Ploegh; Andre Franke; Gregory A Petsko; Vijay K Kuchroo; Richard S Blumberg
Journal:  Nature       Date:  2014-10-26       Impact factor: 49.962

2.  Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs.

Authors:  Shipra Gupta; Thomas B Thornley; Wenda Gao; Rafael Larocca; Laurence A Turka; Vijay K Kuchroo; Terry B Strom
Journal:  J Clin Invest       Date:  2012-06-11       Impact factor: 14.808

Review 3.  TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity.

Authors:  Gordon J Freeman; Jose M Casasnovas; Dale T Umetsu; Rosemarie H DeKruyff
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

4.  Immunization with different viral antigens alters the pattern of T cell exhaustion and latency in herpes simplex virus type 1-infected mice.

Authors:  Sariah J Allen; Kevin R Mott; Mandana Zandian; Homayon Ghiasi
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

Review 5.  Immune checkpoints in central nervous system autoimmunity.

Authors:  Nicole Joller; Anneli Peters; Ana C Anderson; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

6.  Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer's disease.

Authors:  Takashi Mori; Naoki Koyama; Jun Tan; Tatsuya Segawa; Masahiro Maeda; Terrence Town
Journal:  J Biol Chem       Date:  2017-05-16       Impact factor: 5.157

7.  Role of Tim-3/galectin-9 inhibitory interaction in viral-induced immunopathology: shifting the balance toward regulators.

Authors:  Sharvan Sehrawat; Amol Suryawanshi; Mitsuomi Hirashima; Barry T Rouse
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 8.  Immunotherapy for brain cancer: recent progress and future promise.

Authors:  Christopher M Jackson; Michael Lim; Charles G Drake
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

Review 9.  TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.

Authors:  Yoshikane Kikushige; Toshihiro Miyamoto
Journal:  Int J Hematol       Date:  2013-09-18       Impact factor: 2.490

Review 10.  T-cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases.

Authors:  Eoin F McKinney; Kenneth Gc Smith
Journal:  Immunol Cell Biol       Date:  2016-11       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.